Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?

Area of Science:

• Hematology
• Hemostasis
• Pharmacology

Background:

• Severe hemophilia A patients exhibit clinical heterogeneity despite similar factor VIII (FVIII) levels.
• A significant portion of severe hemophilia A patients do not present with a severe bleeding phenotype.
• Predicting bleeding patterns in hemophilia A is crucial for effective prophylactic treatment.

Purpose of the Study:

• To evaluate if global hemostasis tests, thrombin generation assay (TGA) and thromboelastography (TEG), can better predict bleeding patterns in severe hemophilia A compared to trough levels.
• To assess the utility of TGA and TEG in the prophylactic setting for hemophilia A patients.

Main Methods:

• The study included 39 hemophilia A patients and 75 healthy controls.
• Annual bleeding rate (ABR) and Hemophilia Joint Health Score (HJHS) were assessed.
• Basal FVIII levels, inhibitor levels, TEG, and TGA were measured before and after recombinant FVIII administration in patients on prophylaxis.

Main Results:

• Significant differences in ABR and HJHS were observed based on basal FVIII activity post-washout.
• TEG and TGA parameters were significantly better in patients with FVIII activity >1% compared to <1%.
• Post-factor replacement, TEG and TGA parameters were similar between groups, indicating the critical role of baseline levels.

Conclusions:

• A 1% FVIII trough level is critical for both clinical phenotype and thrombin generation in hemophilia A patients on prophylaxis.
• Global hemostasis tests (TGA and TEG) show potential in predicting bleeding phenotypes in hemophilia A.
• The 3% trough level did not appear to be as critical as the 1% level for predicting outcomes.